The US FTC sues e-prescriptions company for an illegal monopolization on two e‑prescribing markets (Surescripts)

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards.

In Short The Situation: The Federal Trade Commission ("FTC") recently filed a rare monopolization case, alleging that a health information technology company illegally monopolized two e‑prescribing markets. The Impact: The FTC continues to aggressively enforce the antitrust laws in the health care industry. Contracts that the FTC believes unfairly lock in customers and harm competitors are likely to receive scrutiny. Looking Ahead: The outcome of this case may help clarify when conduct such as exclusivity, loyalty discounts, or non-compete clauses violate the antitrust laws. This case also signals the FTC's interest in developing law in two-sided markets following the Supreme Court's American Express decision in which the Court held that proof of harm in both sides of a market must be

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Jones Day (Washington DC)
  • Jones Day (Washington DC)
  • Jones Day (Chicago)

Quotation

Aimee DeFilippo, Kenneth W. Field, Michael Sennett, The US FTC sues e-prescriptions company for an illegal monopolization on two e‑prescribing markets (Surescripts), 17 April 2019, e-Competitions April 2019, Art. N° 96736

Visites 38

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues